C4 Therapeutics (CCCC) Operating Leases (2019 - 2026)

C4 Therapeutics has reported Operating Leases for 8 years, with the latest figure at $51.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 11.16% year-over-year to $51.9 million; the trailing twelve-month figure through Mar 2026 stood at $51.9 million (down 11.16% YoY), and the FY2025 full-year result was $53.6 million, down 10.61% from the prior year.
• Operating Leases for Q1 2026 stood at $51.9 million, down from $53.6 million in the prior quarter.
• The five-year high for Operating Leases was $75.2 million in Q2 2022, with the low at $51.9 million in Q1 2026.
• Average Operating Leases over 5 years is $64.1 million, with a median of $64.4 million recorded in 2024.
• Year-over-year, Operating Leases surged 569.59% in 2022 and decreased 11.16% in 2026.
• Tracing CCCC's Operating Leases over 5 years: stood at $71.0 million in 2022, then retreated by 7.35% to $65.8 million in 2023, then retreated by 8.78% to $60.0 million in 2024, then dropped by 10.61% to $53.6 million in 2025, then retreated by 3.15% to $51.9 million in 2026.
• The last three Operating Leases figures came in at $51.9 million (Q1 2026), $53.6 million (Q4 2025), and $55.2 million (Q3 2025), per Business Quant data.

Peer Comparison